GenFleet Therapeutics Achieves Breakthrough Therapy Designation for KRAS G12D Inhibitor in China – A Potential Value Driver for Investors

Key Highlights

• GenFleet Therapeutics (Shanghai) Inc. announced that its oral KRAS G12D (ON/OFF) inhibitor, GFH375, has received the Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE) for treatment of KRAS G12D-mutant non-small cell lung cancer (NSCLC) in patients who have already received at least one prior systemic therapy.
• The BTD was granted based on encouraging Phase I/II data from the GFH375X1101 study, which demonstrated best-in-class monotherapy efficacy and a manageable safety/tolerability profile in NSCLC.
• No targeted therapies for KRAS G12D mutations have yet been approved globally, highlighting a significant unmet medical need. GFH375 is currently among the most advanced programs worldwide for this target.
• Data from GFH375 monotherapy were featured in late-breaking abstracts and oral presentations at major conferences, including the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 World Conference on Lung Cancer, with further updates expected later this year.
• GenFleet is also conducting the world’s first Phase III trial of an oral KRAS G12D inhibitor (GFH375) for metastatic pancreatic cancer, and the compound has received U.S. FDA Fast Track Designation for metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC).
• GFH375 is being developed in China by GenFleet and outside China by partner Verastem Oncology, following a licensing agreement where Verastem holds rights outside China.

Details for Investors and Shareholders

The Breakthrough Therapy Designation (BTD) is a significant milestone as it is designed to expedite the development and regulatory review of drugs with substantial clinical advantage for serious conditions. This status could accelerate the time to market for GFH375 in China and potentially drive significant value for GenFleet if the drug is approved and successfully commercialized.

The KRAS G12D mutation is a major driver in several difficult-to-treat cancers, including NSCLC and PDAC. Currently, there are no approved targeted therapies for KRAS G12D, meaning GFH375 could become a first-in-class or best-in-class therapy, capturing substantial market share in a high-value oncology segment.

The company has demonstrated integrated R&D capabilities with fulzerasib (a KRAS G12C inhibitor that is already marketed), and is now leveraging those capabilities for the G12D mutation. The ongoing and planned trials for GFH375/VS-7375 include multiple monotherapy and combination studies in China and abroad, such as a first-line pancreatic cancer trial in combination with chemotherapy (AG regimen).

Shareholders should note:

• The BTD could significantly accelerate clinical development timelines and regulatory approvals, which may be price-sensitive and could positively affect the company’s share value if further clinical data remains positive.
• GenFleet retains rights to GFH375 in China, while Verastem has development and commercialization rights in all other geographies, enabling GenFleet to benefit from both local and potential global revenues and milestones.
• The advancement of GFH375 into the world’s first Phase III trial for an oral KRAS G12D inhibitor in metastatic pancreatic cancer and its recognition by the U.S. FDA through Fast Track Designation for PDAC further underscores its global development and commercialization potential.
• No approved therapies exist for KRAS G12D mutations, and positive clinical outcomes could position GenFleet as a leader in this field, potentially making the company an attractive partner or acquisition target.

About GFH375/VS-7375

GFH375 is a potent, highly selective, orally active small-molecule inhibitor targeting the KRAS G12D protein, designed to disrupt GTP/GDP exchange and block downstream pathways responsible for tumor cell proliferation. Preclinical studies have shown dose-dependent tumor inhibition and a favorable safety profile, with low off-target activity.

The partnership with Verastem Oncology includes a licensing agreement for three novel oncology programs, with GFH375/VS-7375 as the lead program. Verastem exercised its license for GFH375 in January 2025, granting it rights outside China, while GenFleet retains rights within China.

Management Commentary

Dr. Yu Wang, Chief Medical Officer of GenFleet, emphasized the urgent need for targeted therapies for KRAS G12D-mutant cancers and expressed optimism that the BTD will accelerate clinical development and patient access to GFH375. The company aims to present updated data at global academic events later in the year.

Professor Shun Lu of Shanghai Chest Hospital commented on GFH375’s promising druggability and efficacy, its manageable safety profile, and its potential both as a monotherapy and in combination regimens.

Key Risks and Forward-Looking Statements

Investors are cautioned that although the BTD is a strong positive signal, there is no guarantee that GFH375 will ultimately receive approval or achieve commercial success. The company’s forward-looking statements are subject to risks including market, policy, and R&D uncertainties.

Board and Governance

The Board of GenFleet Therapeutics (Shanghai) Inc. comprises a mix of executive, non-executive, and independent non-executive directors, with Dr. Qiang Lu serving as Chairman and Executive Director.

Disclaimer: This article is for informational purposes only and does not constitute investment, legal, or tax advice. Investors should exercise caution and rely on official company disclosures before making any investment decisions. There is no guarantee that GFH375 or any other pipeline product will be successfully developed, approved, or commercialized.

View GENFLEET-B Historical chart here